The immunology of animal papillomaviruses

Veterinary Immunology and Immunopathology

Volumn 73, Issue 2, 2000, Pages 101-127

  Nicholls, Philip K ^a   Stanley, Margaret A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

DNA vaccine; Papilloma; Vaccine; Virus; Virus like particles (VLP)

Indexed keywords

ANTIBODY; ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELLULAR IMMUNITY; CONTROLLED STUDY; DOG; EPITHELIUM TUMOR; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOLOGY; LARYNX PAPILLOMATOSIS; NONHUMAN; PAPILLOMA; PAPILLOMA VIRUS; RABBIT; REINFECTION; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; CATTLE; DISEASE MODELS, ANIMAL; DOGS; HUMANS; IMMUNITY, CELLULAR; MOUTH NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RABBITS; SKIN NEOPLASMS; TUMOR VIRUS INFECTIONS; VIRAL VACCINES; WARTS;

ANIMALIA; CANIS FAMILIARIS; DNA VIRUSES; ORYCTOLAGUS CUNICULUS; PAPILLOMAVIRUS;

EID: 0033960361     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(99)00165-8     Document Type: Review

References (155)

1. Angell M.G., Christensen N.D., Kreider J.W. An in vitro system for studying the initial stages of cottontail rabbit papillomavirus infection. J. Virol. Meth. 39:1992;207-216.
2. Anonymous, 1989. Sexually-transmitted disease in Britain 1985-1986. Genitourinary Med. 65, 117-121.
3. Bell J.A., Sundberg J.P., Ghim S.J., Newsome J., Jenson A.B., Schlegel R. A formalin-inactivated vaccine protects against mucosal papillomavirus infection-a canine model. Pathobiology. 62:1994;194-198.
4. Beutner K.R., Tyring S. Human papillomavirus and human disease. Am. J. Med. 102:1997;9-15.
5. Bonnez W., Da Rin C., Rose R.C., Reichman R.C. Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J. Gen. Virol. 72:1991;1343-1347.
6. Booy F.P., Roden R.B., Greenstone H.L., Schiller J.T., Trus B.L. Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J. Mol. Biol. 281:1998;95-106.
7. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W.G., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E.G., Rutherford E., Hickling J.K., Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18 E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
8. Brandsma J.L., Brownstein D.G., Xiao W., Longley B.J. Papilloma formation in human foreskin xenografts after inoculation of human papillomavirus type 16 DNA. J. Virol. 69:1995;2716-2721.
9. Bredal W.P., Thoresen S.I., Rimstad E., Aleksandersen M., Nafstad P.H.J. Diagnosis and clinical course of canine oral papillomavirus infection. J. Sm. Anim. Pract. 37:1996;138-142.
10. Bregman C.L., Hirth R.S., Sundberg J.P., Christensen E.F. Cutaneous neoplasms in dogs associated with canine oral papillomavirus vaccine. Vet. Pathol. 24:1987;477-487.
11. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin D.D.C., Orth G., Schiller J.T., Lowy D.R. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:1995;3959-3963.
12. Breitburd F., Salmon J., Orth G. The rabbit viral skin papillomas and carcinomas: a model for the immunogenetics of HPV-associated carcinogenesis. Clin. Dermatol. 15:1997;237-247.
13. Bryan J.T., Jansen K.U., Lowe R.S., Fife K.H., McClowry T., Glass D., Brown D.R. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J. Med. Virol. 53:1997;185-188.
14. Buttner M., Belke-Louis G., Rziha H.J., McInnes C., Kaaden O.R. Detection, cDNA cloning and sequencing of canine interleukin 12. Cytokine. 10:1998;241-248.
15. Campo M.S. Papillomas and cancer in cattle. Cancer Surv. 6:1987;39-54.
16. Campo M.S. Vaccination against papillomavirus in cattle. Clin. Dermatol. 15:1997;275-283.
17. Campo M.S., Grindlay G.J., O'Neil B.W., Chandrachud L.M., McGarvie G.M., Jarrett W.F.H. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74:1993;945-953.
18. Campo M.S., Jarrett W.F., Barron R., O'Neil B.W., Smith K.T. Association of bovine papillomavirus type 2 and bracken fern with bladder cancer in cattle. Cancer Res. 52:1992;6898-6904.
19. Campo M.S., Jarrett W.F., O'Neil W., Barron R.J. Latent papillomavirus infection in cattle. Res. Vet. Sci. 56:1994;151-157.
20. Carter J.J., Galloway D.A. Humoral immune response to human papillomavirus infection. Clin. Dermatol. 15:1997;249-259.
21. Cason J., Kambo P.K., Jewers R.J., Chrystie I.L., Best J.M. Mapping of linear B cell epitopes on capsid proteins of bovine papillomavirus: identification of three external type-restricted epitopes. J. Gen. Virol. 74:1993;2669-2677.
22. Chambers M.A., Zhang W., Coleman N., Nash A.A., Stanley M.A. 'Natural' presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. Eur. J. Immunol. 24:1994;738-745.
23. Chambers V.C., Evans C.A., Weiser R.S. Canine oral papillomatosis II. Immunologic aspects of the disease. Cancer Res. 20:1960;1083-1093.
24. Chandrachud L.M., Grindlay G.J., McGarvie G.M., O'Neil B.W., Wagner E.R., Jarrett W.F.H., Campo M.S. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology. 211:1995;204-208.
25. Chandrachud L.M., O'Neil B.W., Jarrett W.F.H., Grindlay G.J., McGarvie G.M., Campo M.S. Humoral immune response to the E7 protein of bovine papillomavirus type 4 and identification of B-cell epitopes. Virology. 200:1994;98-104.
26. Chen L., Ashe S., Brady W.A., Hellstrom I., Hellstrom K.E., Ledbetter J.A., McGowan P., Linsley P.S. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1992;1093-1102.
27. Chen L.P., Thomas E.K., Hu S.L., Hellstrom I., Hellstrom K.E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA. 88:1991;110-114.
28. Chen Y., Ghim S.-Y., Jenson A.B., Schlegel R. Mutant canine oral papillomavirus L1 capsid proteins which form virus-like particles but lack native conformational epitopes. J. Gen. Virol. 79:1998;2137-2146.
29. Christensen N.D., Cladel N.M., Reed C.A. Postattachment neutralisation of papillomaviruses by monoclonal and polyclonal antibodies. Virology. 207:1995;136-142.
30. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.J., Schlegel R., Jenson A.B., Kreider J.W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 205:1994;329-335.
31. Christensen N.D., Kreider J.W. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J. Virol. 64:1990;3151-3156.
32. Christensen N.D., Kreider J.W., Cladel N.M., Patrick S.D., Welsh P.A. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J. Virol. 64:1990;5678-5681.
33. Christensen N.D., Reed C.A., Cladel N.M., Han R., Kreider J.W. Immunisation with virus-like particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70:1996;960-965.
34. Cierpisz J., Kielbowicz Z., Krol J. The use of autovaccine in atypical case of papillomatosis in a dog. Zycie Weterynaryjne. 68:1993;205-206.
35. Cohn, M.L., Ghim, S.J., Newsome, J., Wlazio, A., Schlegel, R., Bell, J., Sundberg, J., Jenson, A.B., 1997. COPV-specific T cell and antibody responses in infected and vaccinated dogs. 16th International Papillomavirus Conference, University of Siena, Italy, p. 350.
36. Coleman N., Birley H.D., Renton A.M., Hanna N.F., Ryait B.K., Byrne M., Taylor Robinson D., Stanley M.A. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:1994;768-774.
37. Connor M.E., Stern P.L. Loss of MHC class-I expression in cervical carcinomas. Int. J. Cancer. 46:1990;1029-1034.
38. Cook H.R., Olson C. Experimental transmission of cutaneous papilloma of the horse. Am. J. Pathol. 27:1951;1087-1097.
39. Cooper J.E., Lawton M.P., Greenwood A.G. Papillomas in psittacine birds (letter). Vet. Rec. 119:1986;21.
40. de Gruijl T.D., Bontkes H.J., Stukart M.J., Walboomers J.M.M., Remmink A., Verheijen R.H.M., Helmerhost T.J.M., Meijer C.J.L.M., Scheper R. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with persistent viral infection. J. Gen. Virol. 77:1996;2183-2191.
41. DeMonbreun W.A., Goodpasture E.W. Infectious oral papillomatosis in dogs. Am. J. Clin. Pathol. 8:1932;43-55.
42. Dillner J., Lenner P., Lehtinen M., Eklund C., Heino P., Wiklund F., Hallmans G., Stendahl U. A population-based seroepidemiological study of cervical cancer. Cancer Res. 54:1994;134-141.
43. Dillner L., Heino P., Moreno L.J., Dillner J. Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J. Virol. 65:1991;6862-6871.
44. Donnelly J.J., Martinez D., Jansen K.U., Ellis R.W., Montgomery D.L., Liu M.A. Protection against papillomavirus with a polynucleotide vaccine. J. Infect. Dis. 173:1996;314-320.
45. Duncan J.R., Corbeil L.B., Davies D.H., Schultz R.D., Whitlock R.H. Persistent papillomatosis associated with immunodeficiency. Cornell Vet. 65:1975;205-211.
46. Egberink H.F., Berrocal A., Bax H.A., van den Ingh T.S., Walter J.H., Horzinek M.C. Papillomavirus associated skin lesions in a cat seropositive for feline immunodeficiency virus. Vet. Microbiol. 31:1992;117-125.
47. Evans C.A., Gorman L.R., Ito Y., Weiser R.S. Anti-tumour immunity in the Shope papilloma-carcinoma complex of rabbits. I. Papilloma regression induced by homologous and autologous tissue vaccines. J. Nat. Cancer Inst. 29:1962;277-285.
48. Evans C.A., Gormann L.R., Ito Y., Weiser R.S. A vaccination procedure which increases the frequency of regression of Shope papillomas of rabbits. Nature (London). 193:1962;289-290.
49. Evans C.A., Ito Y. Antitumor immunity in the Shope papilloma-carcinoma complex of rabbits. III. Response to reinfection with viral nucleic acid. J. Natl. Cancer Inst. 36:1966;1161-1166.
50. Evans E.M., Man S., Evans A.S., Borysiewicz L.K. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res. 57:1997;2943-2950.
51. Evans I.A., Prorok J.H., Cole R.C., Al-Samani A.H., Al-Samarri A.M., Patel M.C., Smith R.M.N. The carcinogenic, mutagenic and teratogenic toxicity of bracken. Proc. Royal Soc. Edinburgh. 81:1982;65-67.
52. Feltkamp M.C.W., Smits H.L., Vierboom M.P.M., Minnaar R.P., de Jongh B.M., Drijfhout J.W., ter Schegget J., Melief C.J., Kast W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immuno. 23:1993;2242-2249.
53. Gaarenstroom K.N., Kenter G.G., Bonfrer J.M., Korse C.M., Gallee M.P., Hart A.A., Muller M., Trimbos J.B., Helmerhorst T.J. Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. Cancer. 74:1994;2307-2313.
54. Gaspari A.A., Zalka A.D., Payne D., Menegus M., Bunce L.A., Abboud C.N., Tyring S.K. Successful treatment of a generalized human papillomavirus infection with granulocyte-macrophage colony-stimulating factor and interferon gamma immunotherapy in a patient with a primary immunodeficiency and cyclic neutropenia. Arch. Dermatol. 133:1997;491-496.
55. Gaukroger J., Chandrachud L., Jarrett W.F.H., McGarvie G.E., Yeudall W.A., McCaffery R.E., Smith K.T., Campo M.S. Malignant transformation of a papilloma induced by bovine papillomavirus 4 in the nude mouse renal capsule. J. Gen. Virol. 72:1991;1165-1168.
56. Gaukroger J.M., Chandrachud L.M., O'Neil B.W., Grindlay G.J., Knowles G., Campo M.S. Vaccination of cattle with BPV-4 L2 elicits the production of virus neutralising antibodies. J. Gen. Virol. 77:1996;1577-1583.
57. Ghim, S., Newsome, J., Jenson, A.B., Schlegel, R., Suzich, J., Tamura, J., White, W., Hill, F., Warrener, P., Bell, J.A., Sundberg, J., 1995. Formalin-inactivated oral papilloma extracts and recombinant L1 vaccines protect completely against mucosal papillomavirus infection: a canine model. In: Vaccines 95. Laboratory Press, Cold Spring Harbour, pp. 375-379.
58. Ghim, S.J., Newsome, J., Bell, J., Suzich, J.A., Sundberg, J.P., Schlegel, R., Jenson, A.B., 1997a. Spontaneously regressing oral papillomas induce systemic antibodies that neutralise canine oral papillomavirus. 16th International Papillomavirus Conference, University of Siena, Italy, p. 322.
59. Ghim, S.J., Sun, Y.H., Hajo, D., Newsome, J.T.P., Sundberg, J.P., Schlegel, R., Jenson, A.B., 1997b. Recombinant virus-like particles of equine papillomavirus type-1 and its antigenicity. 16th International Papillomavirus Conference, University of Siena, Italy, p. 250.
60. Gröne A., Frisk A.L., Baumgärtner W. Cytokine mRNA expression in whole blood samples from dogs with natural canine distemper virus infection. Vet. Immunol. Immunopathol. 65:1998;11-27.
61. Hamada M., Oyamada T., Yoshikawa H., Yoshikawa T., Itakura C. Histopathological development of equine cutaneous papillomas. J. Comp. Pathol. 102:1990;393-403.
62. Han R., Breitburd F., Marche P.N., Orth G. Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes. Nature. 356:1992;66-68.
63. Han, R., Reed, C.A., Cladel, N.M., Pickel, M.D., Kreider, J.W., Christensen, N.D., 1997. Immunogenicity of CRPV E1, E2, E6 and E7 proteins for T-cell mediated and humoral immune responses in DNA based immunized and CRPV infected rabbits. 16th International Papillomavirus Conference, University of Siena, Italy, p. 354.
64. Han R., Cladel N.M., Reed C.A., Christensen N.D. Intramuscular injection of plasmid DNA encoding cottontail rabbit papillomavirus E1, E2, E6 and E7 induces cell-mediated but not humoral immune responses in rabbits. Vaccine. 17:1999;1558-1566.
65. Han R., Cladel N.M., Reed C.A., Peng X., Christensen N.D. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6 and E7 genes. J. Virol. 73:1999;7039-7043.
66. Harvey S.B., Cadel N.M., Budgeon L.R., Welsh P.A., Griffith J.R., Max Lang C., Christensen N.D. Rabbit genital tissue is susceptible to infection by rabbit oral papillomavirus: an animal model for a genital tissue-targeting papillomavirus. J. Virol. 72:1998;5239-5244.
67. Hayward, M., Meischke, R., Baird, P., Gissman, L., 1992. Filiform squamous papillomas in sheep (OSP)-Clinical features, histology, immunochemistry, transmission experiments and analysis of papillomavirus DNA. 11th International Papillomavirus Workshop, Edinburgh, p. 77.
68. Haywood A.M. Virus receptors: binding, adhesion strengthening, and changes in viral structure. J. Virol. 68:1994;1-5.
69. Hilders C.G., Ras L., van Eendenburg J.D.H., Nooyen Y., Fleuren G.J. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int. J. Cancer. 57:1994;805-813.
70. Hong K., Greer C.E., Ketter N., Van N.G., Paliard X. Isolation and characterization of human papillomavirus type 6-specific T-cells infiltrating genital warts. J. Virol. 71:1997;6427-6432.
71. Hopfl R.M., Christensen N.D., Angell M.G., Kreider J.W. Skin test to assess immunity against cottontail rabbit papillomavirus antigens in rabbits with progressing papillomas or after papilloma regression. J. Invest. Dermatol. 101:1993;227-231.
72. Howett M.K., Christensen N.D., Kreider J.W. Tissue xenografts as a model system for study of the pathogenesis of papillomaviruses. Clin. Dermatol. 15:1997;229-236.
73. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., Martinez D., Ellis R.W., Shaw A.R. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine. 13:1995;1509-1514.
74. Jarrett W.F.H., O'Neil B.W., Gaukroger J.M., Laird H.M., Smith K.T., Campo M.S. Studies on vaccination against papillomaviruses: a comparson of purified virus, tumour extract and transformed cells in prophylactic vaccination. Vet. Rec. 126:1990;449-452.
75. Jarrett W.F.H., O'Neil B.W., Gaukroger J.M., Smith K.T., Laird H.M., Campo M.S. Studies on vaccination against papillomaviruses: the immunity after infection and vaccination with bovine papillomaviruses of different types. Vet. Rec. 126:1990;473-475.
76. Jarrett W.F.H., Smith K.T., O'Neil B.W., Gaukroger J.M., Chandrachud L.M., Grindlay G.J., McGarvie G.M., Campo M.S. Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. Virology. 184:1991;33-42.
77. Kadish A.S., Ho G.Y., Burk R.D., Wang Y., Romney S.L., Ledwidge R., Angeletti R.H. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89:1997;1285-1293.
78. Kidd J.G. The course of virus-induced rabbit papillomas as determined by virus, cells, and host. J. Exp. Med. 67:1938;551-574.
79. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 89:1992;12180-12184.
80. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37-44.
81. Knowles G., O'Neil B.W., Campo M.S. Phenotypical characterisation of lymphocytes infiltrating regressing papillomas. J. Virol. 70:1996;8451-8458.
82. Koller L.D. Cutaneous papillomas on an opossum. J. Nat. Cancer Inst. 49:1972;309-313.
83. Konishi S., Tokita H., Ogata H. Studies on canine oral papillomatosis. I. Transmission and characterization of the virus. J. Vet. Sci. 34:1972;263-268.
84. Kreider J.W. Studies on the mechanism responsible for the spontaneous regression of the Shope rabbit papilloma. Cancer Res. 23:1963;1593-1599.
85. Lambertsen R.H., Kohn B.A., Sundberg J.P., Buergelt C.D. Genital papillomatosis in sperm whale bulls. J. Wildl. Dis. 23:1987;361-367.
86. Lathe, R., Kieny, M.P., Dott, K., Gautier, C., Clertant, F., Cuzin, F., Breitburd, F., Orth, G., Meneguzzi, G., 1989. Vaccination against polyoma and papillomavirus-induced tumors using vaccinia recombinants expressing non-structural proteins. In: Mehens, A., Spier, R.E. (Eds.),Vaccines for Sexually Transmitted Diseases. Butterworth, London, pp. 166-176.
87. Le Net J., Orth G., Sundberg J.P., Cassonnet P., Poisson L., Masson M., George C., Longeart L. Multiple pigmented cutaneous papules associated with a novel canine papillomavirus in an immunosuppressed dog. Vet. Pathol. 34:1997;8-14.
88. Lin Y.L., Borenstein L.A., Ahmed R., Wettstein F.O. Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product. J. Virol. 67:1993;4154-4162.
89. Lin Y.L., Borenstein L.A., Selvakumar R., Ahmed R., Wettstein F.O. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology. 187:1992;612-619.
90. Lin Y.L., Borenstein L.A., Selvakumar R., Ahmed R., Wettstein F.O. Progression from papilloma to carcinoma is accompanied by changes in antibody response to papillomavirus proteins. J. Virol. 67:1993;382-389.
91. Liu X.S., Abdul-Jabbar I., Qi Y.M., Frazer I.H., Zhou J. Mucosal immunisation with papillomavirus virus-like particles elicits systemic and mucosal immunity in mice. Virology. 252:1999;39-45.
92. Lloyd S. Goat medicine and surgery. Brit. Vet. J. 138:1982;70-85.
93. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., Hurni W.M., Joyce J.G., Lehman E.D., Markus H.Z., Neeper M.P., Schultz L.D., Shaw A.R., Jansen K.U. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis. 176:1997;1141-1145.
94. Lucroy M.D., Hill F.I., Moore P.F., Madewell B.R. Cutaneous papillomatosis in a dog with malignant lymphoma following long-term chemotherapy. J. Vet. Diagn. Invest. 10:1998;369-371.
95. M'Fadyean J., Hobday F. Note on the experimental transmission of warts in the dog. J. Comp. Pathol. Therap. 11:1898;341-344.
96. Malejczyk J., Majewski S., Jablonksa S. Cellular immunity in cutaneous and genital HPV infections. Clin. Dermatol. 15:1997;261-274.
97. Mann V.M., De Lao S.L., Brenes M., Brinton L.A., Rawls J.A., Green M., Reeves W.C., Rawls W.E. Occurrence of IgA and IgG antibodies to select peptides representing human papillomavirus type 16 among cervical cancer cases and controls. Cancer Res. 50:1990;7815-7819.
98. McGarvie G.M., Grindlay G.J., Chandrachud L.M., O'Neil B.W., Jarrett W.F.H., Campo M.S. T cell responses to BPV-4 E7 during infection and mapping of T cell epitopes. Virology. 206:1995;504-510.
99. McLean C.S., Sterling J.S., Mowat J., Nash A.A., Stanley M.A. Delayed-type hypersensitivity response to the human papillomavirus type 16 E7 protein in a mouse model. J. Gen. Virol. 74:1993;239-245.
100. Meneguzzi G., Cerni C., Kieny M.P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181:1991;62-69.
101. Meunier L.D. Squamous cell carcinoma in Beagles subsequent to canine oral papillomavirus vaccine. Lab. Anim. Sci. 40:1990;568.
102. Mill A.B., Campbell K.L. Concurrent hypothyroidism, IgM deficiency, impaired T-cell mitogen response, and multifocal cutaneous squamous papillomas in a dog. Canine Pract. 17:1992;15-21.
103. Muller H., Gissmann L. Mastomys natalensis papilloma virus (MnPV), the causative agent of epithelial proliferations: characterization of the virus particle. J. Gen. Virol. 41:1978;315-323.
104. Muller M., Zhou J., Reed T.D., Rittmuller C., Burger A., Gabelsberger J., Braspenning J., Gissmann L. Chimeric papillomavirus-like particles. Virology. 234:1997;93-111.
105. Narayana K., Setty D., Kamalapur P.N., Rao H.S. Treatment of papillomatosis in bovines and canines. Indian J. Anim. Res. 7:1973;40-42.
106. Nasseri M., Wettstein F.O. Differences exist between viral transcripts in cottontail rabbit papillomavirus-induced benign and malignant tumors as well as non-virus-producing and virus-producing tumors. J. Virol. 51:1984;706-712.
107. Nicholls, P.K., Anderson, D.M., Stanley, M.A., 1997. Canine oral papillomavirus-a model for human papillomavirus infection. 16th International Papillomavirus Conference, University of Siena, Italy, p. 189.
108. Nicholls P.K., Klaunberg B.A., Moore R.A., Santos E.B., Parry N.R., Gough W.G., Stanley M.A. Naturally-occurring, non-regressing canine oral papillomavirus infection: host immunity, virus characterisation and experimental infection. Virology. 265:1999;365-374.
109. Okabayashi M., Angell M.G., Budgeon L.R., Kreider J.W. Shope papilloma cell and leukocyte proliferation in regressing and progressing lesions. Am. J. Pathol. 142:1993;489-496.
110. Okabayashi M., Angell M.G., Christensen N.D., Kreider J.W. Morphometric analysis and identification of infiltrating leucocytes in regressing and progressing Shope rabbit papillomas. Int. J. Cancer. 49:1991;919-923.
111. Okabayashi M., Pickel M.D., Budgeon L.R., Cladel N.M., Kreider J.W. Podofilox-induced regression of Shope papillomas may be independent of host immunity. J. Invest. Dermatol. 101:1993;852-857.
112. Okano F., Satoh M., Yamada K. Cloning and expression of the cDNA for canine interleukin-12. J. Interferon Cytokine Res. 17:1997;713-718.
113. Olson C., Segre D., Skidmore L.V. Further observations on immunity to papillomavirus. Am. J. Vet. Res. 21:1960;233-242.
114. Paintsil J., Muller M., Picken M., Gissmann L., Zhou J. Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation. Virology. 223:1996;238-244.
115. Parish W.E. A transmissible genital papilloma of the pig resembling condylomata acuminatum of man. J. Pathol. Bacteriol. 81:1961;331-345.
116. Parish W.E. An immunological study of the transmissible genital papilloma of the pig. J. Pathol. Bacteriol. 83:1962;429-442.
117. Peng S., Frazer I.H., Fernando G., Zhou J. Papilloma virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology. 240:1998;147-157.
118. Phelps W.C., Barnes J.A., Lobe D.C. Molecular targets for human papillomaviruses: prospects for antiviral therapy. Antiviral Chem. Chemother. 9:1998;123-133.
119. Pyrhonen S. Can dogs transmit human warts. Lancet. 2:1976;210.
120. Rajguru D.N., Panchbhai V.S., Pargaonkar D.R., Deshpande B.B. A clinical report on cutaneous caprine papillomatosis. Ind. Vet. J. 65:1988;827-828.
121. Roden R.B., Greenstone H.L., Kirnbauer R., Booy F.P., Jessie J., Lowy D.R., Schiller J.T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:1996;5875-5883.
122. Roden R.B., Weissinger E.M., Henderson D.W., Booy F., Kirnbauer R., Mushinski J.F., Lowy D.R., Schiller J.T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68:1994;7570-7574.
123. Roden R.B.S., Kirnbauer R., Jenson A.B., Lowy D.R., Schiller J.T. Interaction of papillomaviruses with the cell surface. J. Virol. 68:1994;7260-7266.
124. Rose R.C., Lane C., Wilson S., Suzich J.A., Rybicki E., Williamson A.L. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine. 17:1999;2129-2135.
125. Salmon J., Ramoz N., Cassonnet P., Orth G., Breitburd F. A cottontail rabbit papillomavirus strain (CRPVb) with strikingly divergent E6 and E7 oncoproteins: an insight in the evolution of papillomaviruses. Virology. 235:1997;228-234.
126. Schiller J.T. Papillomavirus-like particle vaccines for cervical cancer. Mol. Med. Today. 5:1999;209-215.
127. Selvakumar R., Ahmed R., Wettstein F.O. Tumor regression is associated with a specific immune response to the E2 protein of cottontail rabbit papillomavirus. Virology. 208:1995;298-302.
128. Selvakumar R., Borenstein L.A., Lin Y.L., Ahmed R., Wettstein F.O. T-cell response to cottontail rabbit papillomavirus structural proteins in infected rabbits. J. Virol. 68:1994;4043-4048.
129. Selvakumar R., Borenstein L.A., Lin Y.L., Ahmed R., Wettstein F.O. Immunization with nonstructural proteins E1 and E2 of cottontail rabbit papillomavirus stimulates regression of virus-induced papillomas. J. Virol. 69:1995;602-605.
130. Selvakumar R., Schmitt A., Iftner T., Ahmed R., Wettstein F.O. Regression of papillomas induced by cottontail rabbit papillomavirus is associated with infiltration of CD8+ cells and persistence of viral DNA after regression. J. Virol. 71:1997;5540-5548.
131. Shepherd P.S., Rowe A.J., Cridland C.J., Coletart T., Wilson P., Luxton J.C. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia. J. Gen. Virol. 77:1996;593-602.
132. Shope R.E. Immunization of rabbits to infectious papillomatosis. J. Exp. Med. 65:1937;219-231.
133. Shope R.E. Infectious papillomatosis of rabbits with a note on the histopathology. J. Exp. Med. 58:1933;607-624.
134. Stanley M. Genital human papillomaviruses - prospects for vaccination. Curr. Opin. Infect. Dis. 10:1997;55-61.
135. Stanley M.A., Masterson P.J., Nicholls P.K. In vitro and animal models for antiviral therapy in papillomavirus infections. Antiviral Chem. Chemother. 8:1997;381-400.
136. Steele J.C., Gallimore P.H. Humoral assays of human sera to disrupted and non-disrupted epitopes of human papillomavirus type 1. Virology. 174:1990;388-398.
137. Sundaram P., Tigelaar R.E., Brandsma J.L. Intracutaneous vaccination of rabbits with the cottontail rabbit papillomavirus (CRPV) L1 gene protects against virus challenge. Vaccine. 15:1997;664-671.
138. Sundaram P., Tigelaar R.E., Xiao W., Brandsma J.L. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine. 16:1998;613-623.
139. Sundaram P., Xiao W., Brandsma J.L. Particle-mediated delivery of recombinant expression vectors to rabbit skin induces high-titered polyclonal antisera (and circumvents purification of a protein immunogen). Nucleic Acids Res. 24:1996;1375-1377.
140. Sundberg J.P., Chiodini R.J., Nielsen S.W. Transmission of the white-tailed deer cutaneous fibroma. Am. J. Vet. Res. 46:1985;1150-1154.
141. Sundberg J.P., Russell W.C., Lancaster W. Papillomatosis in Indian elephants. J. Am. Vet. Med. Assoc. 179:1981;1247-1248.
142. Sundberg J.P., Smith E.K., Herron A.J., Jenson A.B., Burk R.D., Van Ranst M. Involvement of canine oral papillomavirus in generalized oral and cutaneous verrucosis in a Chinese Shar Pei dog. Vet. Pathol. 31:1994;183-187.
143. Suzich J.A., Ghim S., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA. 92:1995;11553-11557.
144. Tan J., Yang N.S., Turner J.G., Niu G.L., Maassab H.F., Sun J., Herlocher M.L., Chang A.E., Yu H. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther. 6:1999;331-339.
145. Tang D.C., DeVit M.J., Johnston S.A. Genetic immunization: a simple method for eliciting an immune response. Nature. 356:1992;152-154.
146. Theilen G., Wheeldon E.B., East N., Madewell B., Lancaster W.D., Munn R. Goat papillomatosis. Am. J. Vet. Res. 46:1985;2519-2526.
147. Thomen, A.A., 1938. Doctors Don't Believe It. J. M. Dent & Sons, London, pp 308-310.
148. Tuting T., Storkus W.J., Falo L.D. DNA immunization targeting the skin: molecular control of adaptive immunity. J. Invest. Dermatol. 111:1998;183-188.
149. Unckell F., Streeck R.E., Sapp M. Generation and neutralization of pseudovirions of human papillomavirus type. J. Virol. 71:1997;2934-2939.
150. Walder, E.J., 1992. Viral squamous papilloma. In: T.L. Gross, P.J. Ihrke, E.J. Walder (Eds.), Veterinary Dermatopathology: a Macroscopic and Microscopic Evaluation of Canine and Feline Skin Disease. Mosby-Year Book, St Louis, pp. 334-335.
151. Wettstein, F.O., 1987. Papillomaviruses and carcinogenic progression, I. Cottontail rabbit (Shope) papillomavirus. In: Salzman, Howley, P.M. (Eds.), The Papovaviridae, Vol. 2. Plenum, New York, pp. 167-186.
152. White W.J., Wilson S.D., Bonnez W., Rose R.C., Koenig S., Suzich J.A. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J. Virol. 72:1998;959-964.
153. Zhou J., Stenzel D.J., Sun X.Y., Frazer I.H. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J. Gen. Virol. 74:1993;763-768.
154. Zhou J., Sun X.Y., Louis K., Frazer I.H. Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J. Virol. 68:1994;619-625.
155. Zucker K., Lu P., Asthana D., Carreno M., Yang W.C., Esquenazi V., Fuller L., Miller J. Production and characterization of recombinant canine interferon-gamma from Escherichia coli. J. Interferon Res. 13:1993;91-97.